TIDMVENN

RNS Number : 9166Y

Venn Life Sciences Holdings PLC

28 February 2013

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Director's Dealing

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that David Evans, Non Executive Chairman of the Company, has transferred 12,368 ordinary shares from his own name into his pension fund. The shares were transferred at a price of 31.5p

There has been no change in David Evans' beneficial shareholding in Venn as a result of these transactions.

 
 Enquiries: 
Venn Life Sciences Holdings Plc 
Tony Richardson, Chief Executive      Tel: +353 154 99 341 
 Officer 
Paul Foulger, Finance Director        Tel: 020 7245 1100 
 
Zeus Capital (Nominated Adviser and 
 Broker) 
Ross Andrews/Andrew Jones (Corporate  Tel: 0161 831 1512 
 Finance) 
John Goold (Institutional Sales)      Tel: 020 7016 8925 
 
Walbrook PR Ltd                       Tel: 020 7933 8787 or 
                                       Mob: 07980 541 893 
Paul McManus                          paul.mcmanus@walbrookpr.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSLLFSFFRITFIV

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Hvivo
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Hvivo